Stay updated on SL-401 Combo With Pomalid/Dex in MM Clinical Trial

Sign up to get notified when there's something new on the SL-401 Combo With Pomalid/Dex in MM Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SL-401 Combo With Pomalid/Dex in MM Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:39:44.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value of SL-401 has changed from 7 µg/kg/day to 8 µg/kg/day in the study of SL-401 in Combination with Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma. This change represents an adjustment in the dosage of SL-401 being tested in the clinical trial.
    Difference
    0.1%
    Check dated 2024-06-06T14:37:10.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide detailed eligibility criteria for patient inclusion in the study, including specific health conditions and prior treatments required. This replaces the previous placeholder text indicating no information was provided for collaborators and investigators.
    Difference
    32%
    Check dated 2024-05-22T21:14:28.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.5%
    Check dated 2024-04-30T22:56:24.000Z thumbnail image

Stay in the know with updates to SL-401 Combo With Pomalid/Dex in MM Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SL-401 Combo With Pomalid/Dex in MM Clinical Trial page.